@article{fdi:010064863, title = {{D}eveloping vaccines to prevent malaria in pregnant women}, author = {{T}uikue {N}dam, {N}icaise and {D}eloron, {P}hilippe}, editor = {}, language = {{ENG}}, abstract = {{I}ntroduction: {P}lacental malaria ({PM}) is a major public health problem that constitutes a significant health concern for the mother, and especially for the developing fetus and offspring. {C}urrent means of prevention have limitations, including a restricted window of intervention that excludes the first trimester of pregnancy, and the fact that very few drugs can be used for this purpose. {T}he identification of the {VAR}2{CSA} antigen, specific to {PM} parasites, offers an excellent opportunity to develop a vaccine against this disease. {P}roof of concept of a first-generation vaccine is nearing completion, and two clinical trials are underway. {A}reas covered: {T}his review focuses on {PM}, which is mainly caused by {P}lasmodium falciparum. {T}he review highlights recent advances and the key milestones that led to the identification of the optimal vaccine target within the large {VAR}2{CSA} protein. {T}he paper also points out how future improvements can strengthen this process to achieve an effective vaccine in the field. {E}xpert opinion: {T}he approach taken to develop a {P}. falciparum erythrocyte membrane protein 1-based vaccine to protect pregnant women is very promising in view of the current difficulties of achieving a sterilizing vaccine against malaria parasite. {T}his approach could help us to control the deleterious effect of malaria infections that characterize severe clinical forms.}, keywords = {malaria ; {P}f{EMP}1 ; {P}lasmodium falciparum ; pregnancy ; vaccine ; {VAR}2{CSA} ; {AFRIQUE} {SUBSAHARIENNE} ; {BENIN}}, booktitle = {}, journal = {{E}xpert {O}pinion on {B}iological {T}herapy}, volume = {15}, numero = {8}, pages = {1173--1182}, ISSN = {1471-2598}, year = {2015}, DOI = {10.1517/14712598.2015.1049595}, URL = {https://www.documentation.ird.fr/hor/fdi:010064863}, }